Latest News about Next/Generation Psychedelics
Recent news which mentions Next/Generation Psychedelics
Enveric Biosciences Optimistic On Q4 And Full-Year Results: 'Psychedelic-Inspired' Meds For Future Growth
March 27, 2024
Tickers
ENVB
From Benzinga
Fed Agency Grants $14M To Gilgamesh For Cardiac-Safe Ibogaine Analog Targeting Opioid Use Disorder
March 15, 2024
Tickers
NEWS
From Benzinga
Cybin's Novel Psilocybin Topline Data: 79% Remission In Major Depression Symptoms, What's Next?
December 03, 2023
Tickers
CYBN
From Benzinga
Clearmind Medicine's Reverse Stock Split And Nasdaq Delisting Notice
November 21, 2023
Tickers
CMND
From Benzinga
Enveric Biosciences' Revenue Drops In Q3 2023 As Next-Gen Psychedelics Advance To Clinical Trials
November 14, 2023
Tickers
ENVB
From Benzinga
Atai Life Sciences' Q3 Earnings: Near $20M Burned QoQ, Says Funding 'Sufficient' To Streamline 2026
November 14, 2023
From Benzinga
Hope For Postpartum Depression: This Company To Launch Clinical Trial On Next-Gen Psychedelic
September 18, 2023
Tickers
MSSTF
From Benzinga
Johns Hopkins Will Work With Clearmind On Alcohol Addiction Research Program
September 06, 2023
Tickers
CMND
From Benzinga
From Benzinga
Psychedelics IP Protection: Cybin Nabs US Patent For Deuterated Analogs, Psilera Advances Next-Gen Library
August 16, 2023
Tickers
CYBN
From Benzinga
Enveric's Q2 2023 Financials Show Immediate Need For Budget-Slimming Toward A Clinical-Staged 2024
August 14, 2023
Tickers
ENVB
From Benzinga
Bright Mind Shares Surge 91% After Reporting Positive EEG Clinical Results Of Next-Gen Compound
August 08, 2023
Tickers
DRUG
From Benzinga
Reunion Neuroscience Completes Take-Private Setup: Delisting & Consideration Details
August 01, 2023
Tickers
REUN
From Benzinga
From Benzinga
From Benzinga
Pioneering Psychedelics Scientist Alexander "Sasha" Shulgin's Legacy Lives On Via New Compounds And Research
July 10, 2023
From Benzinga
This Biotech Is Entering The Clinical Stage With A Psilocin Analog Targeting Cluster Headaches
June 28, 2023
Tickers
LOBEF
From Benzinga
BetterLife Fast Tracks Its US Patent For Non-Hallucinogenic Compound And Other LSD Derivatives
June 28, 2023
From Benzinga
Cybin's FY2023 Financials, Guidance And Appointment Of Sanford R. Climan As Strategic Advisor
June 28, 2023
Tickers
CYBN
From Benzinga
UK Greenlights Phase 2 Clinical Trial On Mindset Pharma's Psilocin Drug For Major Depression
June 27, 2023
Tickers
MSSTF
From Benzinga
Canadian Financing: PharmAla Biotech Offers Non-Brokered Private Placement Up To $3.76M
June 13, 2023
Tickers
PMBHF
From Benzinga
Mydecine's Prospectus Supplement Closing Under Share Subscription And Management Update
May 30, 2023
Tickers
MYCOF
From Benzinga
This Company's Psilocybin-Based Non Hallucinogenic Compound Heads Toward Clinical Studies
May 28, 2023
From Benzinga
Promising Multiple Sclerosis Drug Candidate Advances: First Clinical Trial Dosing Completed
May 10, 2023
Tickers
HUGE
From Benzinga
From Benzinga
NY Biotech Gets International IP Coverage For Growing Portfolio Of Psychedelic-Derived Novel Drugs
May 05, 2023
From Benzinga
This Firm Bets On Non-Hallucinogenic Psychedelics, Files Claims For International IP Protection
April 26, 2023
Tickers
MSSTF
From Benzinga